BioCentury | Apr 3, 2021
Deals

April 2 Quick Takes: Agios begins share buybacks upon closing Servier deal, plus Royalty-GSK, Gracell-Lonza, Alloy, Eloxx-Zikani and Angelini-Ovid

...which is entitled to a 3% royalty on worldwide sales via a 2002 deal with Exelixis Inc....
BioCentury | Mar 31, 2021
Regulation

March 31 Quick Takes: Basket of EU approvals includes MS, SMA drugs; plus Amarin, AbbVie, Cara-Vifor

...additional cardiovascular risk factor.Other European approvals this week included Cabometyx cabozantinib from Ipsen (Euronext:IPN; Pink:IPSEY) and Exelixis Inc....
BioCentury | Feb 10, 2021
Product Development

First-line RCC immunotherapy combinations shine at ASCO GU

...preferred treatment. Bristol Myers Squibb Co. (NYSE:BMY) and Exelixis Inc....
BioCentury | Feb 9, 2021
Product Development

Opdivo makes rare hit in adjuvant muscle-invasive bladder cancer

...Opdivo and kinase inhibitor Cabometyx cabozantinib from Exelixis Inc....
...month to treat first-line RCC.At ASCO GU, Exelixis...
...#), BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) Exelixis Inc. Bristol...
BioCentury | Feb 2, 2021
Deals

Feb. 1 Quick Takes: Coherus gets rights to Junshi’s PD-1; plus GSK backs newco Adrestia, a seed for Cellino and more

...machine learning, single-cell laser processing and robotics. Exelixis partners with Adagene on masked ADCsAdagene Inc. granted Exelixis Inc....
...to use its SAFEbody technology for the design of antibody-drug conjugates or other therapies from Exelixis...
BioCentury | Jan 22, 2021
Product Development

Jan. 22 Quick Takes: CDC updates advice on COVID vaccine dosing; plus more vaccines for COVAX and RCC approval for Opdivo-Cabometyx and more

...yields approval in RCCFDA approved Opdivo nivolumab from Bristol Myers Squibb Co. (NYSE:BMY) and Cabometyx cabozantinib from Exelixis Inc....
...a COVID-19 patient over the course of the disease. TARGETSLAG3 (CD223) – Lymphocyte-activation gene 3 BC Staff Pfizer Inc. Exelixis Inc. GlaxoSmithKline...
BioCentury | Dec 12, 2020
Product Development

Ipsen is casting a wider BD net under new CEO Loew

...year, represents Ipsen’s best near-term growth prospect. However, partner Exelixis Inc....
BioCentury | Dec 10, 2020
Deals

More enthusiasm for ADCs as Boehringer buys NBE, gaining conjugate platform

...the target of which is undisclosed; as well as programs partnered with Sotio a.s. and Exelixis Inc....
BioCentury | Dec 3, 2020
Finance

Dec. 2 Quick Takes: venture rounds for Genesis, Biosight; plus: Frontier-AbbVie, Exelixis-Iconic, UCB-Specifica and Click

...and is eligible for more than $1 billion in milestones, plus royalties. Exelixis in-licenses ADC from Iconic Exelixis Inc....
...treat cognitive and neurobehavioral disorders. TARGETSTF (CD142; thromboplastin) – Tissue factor BC Staff Genesis Therapeutics Inc. AbbVie Inc. Frontier Medicines Corp. Exelixis Inc. Iconic...
BioCentury | Sep 23, 2020
Product Development

Immunomedics data point to Trodelvy’s $21B potential

...Clinical Oncology (ASCO) meeting in May (see “ASCO Data Bring New Markets Within Reach”). BMS and Exelixis Inc....
...Generic), Opdivo (Other) Cometriq (Brand), Cabometyx (Brand), XL184 (Compound #), cabozantinib (Generic), Cometriq (Other), Cabometyx (Other) Amgen Inc. Exelixis Inc. Immunomedics...
Items per page:
1 - 10 of 971
BioCentury | Apr 3, 2021
Deals

April 2 Quick Takes: Agios begins share buybacks upon closing Servier deal, plus Royalty-GSK, Gracell-Lonza, Alloy, Eloxx-Zikani and Angelini-Ovid

...which is entitled to a 3% royalty on worldwide sales via a 2002 deal with Exelixis Inc....
BioCentury | Mar 31, 2021
Regulation

March 31 Quick Takes: Basket of EU approvals includes MS, SMA drugs; plus Amarin, AbbVie, Cara-Vifor

...additional cardiovascular risk factor.Other European approvals this week included Cabometyx cabozantinib from Ipsen (Euronext:IPN; Pink:IPSEY) and Exelixis Inc....
BioCentury | Feb 10, 2021
Product Development

First-line RCC immunotherapy combinations shine at ASCO GU

...preferred treatment. Bristol Myers Squibb Co. (NYSE:BMY) and Exelixis Inc....
BioCentury | Feb 9, 2021
Product Development

Opdivo makes rare hit in adjuvant muscle-invasive bladder cancer

...Opdivo and kinase inhibitor Cabometyx cabozantinib from Exelixis Inc....
...month to treat first-line RCC.At ASCO GU, Exelixis...
...#), BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) Exelixis Inc. Bristol...
BioCentury | Feb 2, 2021
Deals

Feb. 1 Quick Takes: Coherus gets rights to Junshi’s PD-1; plus GSK backs newco Adrestia, a seed for Cellino and more

...machine learning, single-cell laser processing and robotics. Exelixis partners with Adagene on masked ADCsAdagene Inc. granted Exelixis Inc....
...to use its SAFEbody technology for the design of antibody-drug conjugates or other therapies from Exelixis...
BioCentury | Jan 22, 2021
Product Development

Jan. 22 Quick Takes: CDC updates advice on COVID vaccine dosing; plus more vaccines for COVAX and RCC approval for Opdivo-Cabometyx and more

...yields approval in RCCFDA approved Opdivo nivolumab from Bristol Myers Squibb Co. (NYSE:BMY) and Cabometyx cabozantinib from Exelixis Inc....
...a COVID-19 patient over the course of the disease. TARGETSLAG3 (CD223) – Lymphocyte-activation gene 3 BC Staff Pfizer Inc. Exelixis Inc. GlaxoSmithKline...
BioCentury | Dec 12, 2020
Product Development

Ipsen is casting a wider BD net under new CEO Loew

...year, represents Ipsen’s best near-term growth prospect. However, partner Exelixis Inc....
BioCentury | Dec 10, 2020
Deals

More enthusiasm for ADCs as Boehringer buys NBE, gaining conjugate platform

...the target of which is undisclosed; as well as programs partnered with Sotio a.s. and Exelixis Inc....
BioCentury | Dec 3, 2020
Finance

Dec. 2 Quick Takes: venture rounds for Genesis, Biosight; plus: Frontier-AbbVie, Exelixis-Iconic, UCB-Specifica and Click

...and is eligible for more than $1 billion in milestones, plus royalties. Exelixis in-licenses ADC from Iconic Exelixis Inc....
...treat cognitive and neurobehavioral disorders. TARGETSTF (CD142; thromboplastin) – Tissue factor BC Staff Genesis Therapeutics Inc. AbbVie Inc. Frontier Medicines Corp. Exelixis Inc. Iconic...
BioCentury | Sep 23, 2020
Product Development

Immunomedics data point to Trodelvy’s $21B potential

...Clinical Oncology (ASCO) meeting in May (see “ASCO Data Bring New Markets Within Reach”). BMS and Exelixis Inc....
...Generic), Opdivo (Other) Cometriq (Brand), Cabometyx (Brand), XL184 (Compound #), cabozantinib (Generic), Cometriq (Other), Cabometyx (Other) Amgen Inc. Exelixis Inc. Immunomedics...
Items per page:
1 - 10 of 971